Heather J Alker, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: Isis Maternity, Needham, MA 02494 Phone: 781-429-1500 |
Renee M Goldberg, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 272 Chestnut St, Beth Israel Hosp Med Car, Needham, MA 02492 Phone: 781-433-0214 |
Dr. Susan V.g. Lincoln, M.D. Obstetrics & Gynecology - Obstetrics Medicare: Accepting Medicare Assignments Practice Location: 392 Chestnut St, 2nd Floor, Needham, MA 02492 Phone: 617-754-1800 Fax: 617-754-1820 |
Carolyn V Shaak, HD Obstetrics & Gynecology - Gynecology Medicare: Not Enrolled in Medicare Practice Location: 405 Great Plain Avenue, Needham, MA 02492 Phone: 781-453-2927 Fax: 781-453-2966 |
Dr. Patricia Rose Falcao, MD,MPH,FACOG,FASAM Obstetrics & Gynecology - Gynecology Medicare: Not Enrolled in Medicare Practice Location: 19 Pine St, Needham, MA 02492 Phone: 781-444-5425 |
News Archive
A systematic review from the University of Alabama at Birmingham shows that routinely opting for a repeat cesarean delivery over first attempting a vaginal delivery may result in excess morbidity and cost from a population perspective for women with a prior low transverse incision cesarean delivery who are likely to have a successful vaginal delivery.
Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment.
A new study from neuroscientists at the Wayne State University School of Medicine provides the first novel insights into the neural origins of hot flashes in menopausal women in years. The study may inform and eventually lead to new treatments for those who experience the sudden but temporary episodes of body warmth, flushing and sweating.
Health insurer Humana said in quarterly filings Monday that the Department of Justice is investigating its coding practices by doctors in South Florida as well as loans made to doctor practices.
Axelar AB today announced that promising data from the ongoing Phase I/II clinical trial concerning their lead anticancer product AXL1717, an insulin-like growth factor-1 (IGF-1) receptor inhibitor, will be presented next week at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, Massachusetts, USA.
› Verified 8 days ago